NeoGenomics, Inc. (NASDAQ:NEO) Q4 2023 Earnings Call Transcript
NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $-0.01.
Neogenomics Inc (NEO)
Market is closed
Sector: Services-Testing Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Greenhouse Funds Joe Milano | 4,333,031 | $70,108,442 | +9% | 4.61% |
| 2. | 65,601,000 | $50,199,537 | +5% | 1.84% | |
| 3. | 17,500,000 | $13,275,695 | 0.01% | ||
| 4. | Driehaus Capital Richard Driehaus | 781,735 | $12,648,472 | +77% | 0.15% |
| 5. | Royce & Associates Chuck Royce | 591,442 | $9,569,532 | -1% | 0.08% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $30.63 | 17,000 | Officer, Director | 72,736 | 2021-12-06 | Filing | |
| $11.60 | 26,000 | Director | 103,866 | 2018-12-21 | Filing | |
| $9.19 | 20,000 | Director | 38,782 | 2017-07-27 | Filing | |
| $6.75 | 14,800 | Director | 110,547 | 2016-03-03 | Filing | |
| $6.84 | 7,207 | Director | 117,754 | 2016-03-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.97 | 6,112 | Director | 50,062 | 2024-03-04 | Filing | |
| $14.96 | 2,587 | Officer | 34,866 | 2024-02-15 | Filing | |
| $18.39 | 2,669 | Officer | 37,140 | 2023-11-17 | Filing | |
| $18.29 | 3,209 | Officer | 98,516 | 2022-03-07 | Filing | |
| $35.00 | 1,846 | Officer | 11,689 | 2021-12-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 19,980,993 | $323,292,467 | 0% | |
| 2. | 14,169,665 | $229,265,180 | 0% | |
| 3. | 9,643,599 | $156,033,435 | 0.21% | |
| 4. | 6,348,613 | $102,720,237 | 0.06% | |
| 5. | 4,844,945 | $78,391,210 | 0% |
News See All
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2023 Earnings Call Transcript
Operator: Greetings. Welcome to the NeoGenomics Third Quarter 2023 Earnings Call -- Third Quarter 2023 Financial Results Conference Call and Webcast.
Top 20 Genomics Companies in the World
In this piece, we will take a look at the top 20 genomics companies in the world.
NeoGenomics, Inc. (NASDAQ:NEO) Q2 2023 Earnings Call Transcript
Operator: Welcome to the NeoGenomics Second Quarter 2023 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2023 Earnings Call Transcript
Operator: Welcome to the NeoGenomics First Quarter 2023 Financial Results Conference Call and Webcast. At this time all participants are in listen only mode.
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2022 Earnings Call Transcript
Operator: Good morning. Welcome to the NeoGenomics Fourth Quarter and Full Year 2020 Earnings Conference Call.
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2022 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the NeoGenomics Third Quarter 2022 Earnings Call.
12 Biggest Genomics Companies In The World
In this article, we will discuss the 12 Biggest Genomics Companies In The World.
Here's How Artisan Partners Views NeoGenomics (NEO)
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here.
Is it Still Worthy to Invest in NeoGenomics (NEO)?
Carillon Tower Advisers, an investment management firm, published its “Carillon Scout Small Cap Fund” first quarter 2022 investor letter – a copy of which can be downloaded here.
Billionaire Hedge Funds
